Welcome to our dedicated page for Jupiter Wellness news (Ticker: jupw), a resource for investors and traders seeking the latest updates and insights on Jupiter Wellness stock.
Jupiter Wellness, Inc. (JUPW) drives innovation in CBD-infused therapeutic products, from sun care lotions to advanced dermatological solutions. This page serves as the definitive source for verified company updates, offering stakeholders timely access to official announcements.
Find curated press releases covering new product launches across Canisun, Caniskin, and CanidermRx brands, regulatory milestones in the CBD sector, financial disclosures, and strategic partnerships. Each update is sourced directly from Jupiter Wellness to ensure accuracy and compliance with financial reporting standards.
Investors and industry observers can use this resource to monitor JUPW's growth in the competitive wellness market. Bookmark this page for efficient tracking of the company's advancements in CBD research and consumer product development.
Jupiter Wellness (NASDAQ:JUPW) has licensed its minoxidil booster technology to Taisho Pharmaceutical for the Japanese market. This innovation targets Androgenetic Alopecia patients who do not respond to conventional minoxidil treatments. The minoxidil booster, developed by Applied Biology, enhances the drug's efficacy by utilizing the sulfotransferase enzyme (SULT1A1). With Taisho being Japan's leading minoxidil producer, this collaboration aims to improve outcomes for hair loss patients. This advancement may positively impact Jupiter's market presence and revenue streams.
Jupiter Wellness, Inc. (NASDAQ:JUPW) announced the appointments of Dr. Andy Goren as Chief Medical Officer and Dr. John McCoy as Vice President of R&D, enhancing their leadership team. Dr. Goren brings over 20 years of experience in clinical development and has pioneered several dermatological tests. Dr. McCoy, with a strong background in biophysics, has developed new topical formulations and contributed to COVID-19 treatment research. These appointments are expected to bolster Jupiter's R&D and contribute to its diverse healthcare product pipeline.
Jupiter Wellness (Nasdaq: JUPW) announced the acquisition of Applied Biology, a biotechnology firm focused on skin and hair science. The deal involves up to 4 million shares contingent on milestone achievements. Applied Biology reported approximately $8 million in revenue and $3 million in EBITDA in 2021. The acquisition is expected to enhance Jupiter's growth, expand its product pipeline, and integrate Applied Biology's clinical expertise. Notable products include Photocil for psoriasis and treatments for women's health. The move potentially positions Jupiter for significant financial gains.
Jupiter Wellness (NASDAQ:JUPW) announced the retirement of 2,433,894 common shares, reducing outstanding shares to 22,151,528, approximately 10% lower. This move is part of a $5.0 million share buyback program, with the company expressing a belief that its stock is currently undervalued. CEO Brian John emphasized that this buyback reflects their commitment to shareholders and the strategic use of capital to enhance future growth.
Jupiter Wellness (NASDAQ: JUPW) announced the appointment of Paul Jones as Senior Project Manager on June 2, 2022. With over 20 years of experience, Jones previously managed projects at a South Florida investment firm and was part of Ferrari’s project management team. His expertise will enhance Jupiter's product pipeline for skincare therapeutics, incorporating cannabidiol (CBD) for conditions like psoriasis and skin cancer. The company continues to expand its proprietary skincare products, aiming to maximize growth and development.
Jupiter Wellness (NASDAQ:JUPW) will present findings from its clinical trial on JW-300, a cannabidiol topical treatment for first-degree burns, at the SCALE 2022 Conference in Nashville from May 11-15, 2022. The trial, involving 36 patients, demonstrated that JW-300 significantly reduced the incidence of burns compared to placebo (27% vs. 61%, p=0.047). Dr. Glynn Wilson highlighted its potential to prevent sunburn and skin cancer. CEO Brian John noted that JW-300 complements their existing skincare products, catering to a growing market for effective solutions.
Jupiter Wellness has successfully acquired assets from Ascent Clinical Research to expand its research capabilities and enter the clinical research organization sector. The acquisition includes contracts valued at $3 million in annual revenues, with Jupiter paying only 5% royalties on future net revenues generated. This strategic move is expected to enhance EBITDA without upfront cash costs and bolster Jupiter's position in research and development. The deal is anticipated to contribute to immediate revenues starting in Q2 2022.
Jupiter Wellness, Inc. (NASDAQ: JUPW) has appointed three new sales and marketing executives to enhance the performance of its proprietary wellness brands. The team includes Mohammed Ahmed, Jennifer Canon, and Guy Shapira, each bringing substantial experience in marketing, product development, and digital strategy. Jupiter has a portfolio of award-winning wellness brands and aims to grow revenues from these existing and new products. CEO Brian John expressed confidence in the team's ability to maximize the consumer products division while continuing clinical advancements in dermatology.
Jupiter Wellness (NASDAQ:JUPW) has announced the launch of CaniSun for Shark Defense, a new sunscreen product incorporating patented shark repellent technologies licensed from Shark Defense Technologies. This innovation aims to enhance sun and skincare products while addressing the increasing incidence of unprovoked shark bites globally. Jupiter plans to unveil CaniSun in Q3 2022, further expanding its line of reef-friendly skincare solutions. The collaboration is set to foster advancements in shark repellent formulations.
Jupiter Wellness (NASDAQ:JUPW) has announced the publication of clinical trial results for its proprietary lotion, JW-100, aimed at treating atopic dermatitis. The study, published in the Journal of Cosmetic Dermatology, involved 57 participants and demonstrated significant improvement in atopic dermatitis symptoms. 50% of JW-100 users achieved an ISGA score of clear or almost clear after 14 days, compared to 20% and 15% in the CBD-only and placebo groups, respectively. The company is advancing JW-100 through FDA drug development protocols.
